INCA035784
/ Incyte
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
July 10, 2025
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
(clinicaltrials.gov)
- P1 | N=120 | Recruiting | Sponsor: Incyte Corporation | Not yet recruiting ➔ Recruiting
Enrollment open • Myeloproliferative Neoplasm • Oncology
May 16, 2025
INCA035784, A NOVEL, EQUIPOTENT T CELL–REDIRECTING ANTIBODY FOR PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS CARRYING DIFFERENT TYPES OF CALRETICULIN MUTATIONS
(EHA 2025)
- "INCA035784 does not bind to wtCALR when a stress agent such as doxorubicin induces its translocation to the cell surface...INCA035784 induced minimal levels of CRS-associated cytokines from HD PBMCs, HD T cells, and patient-derived PBMCs vs other T cell-engaging antibodies such as mosunetuzumab and vibecotamab, targeting CD20 and CD123, respectively... Overall, INCA035784 activates T cells in the presence of mutCALR complexed with TPOR on the cell surface. By binding to a unique, conserved epitope on the mutCALR N-domain, INCA035784 can target the diverse mutCALR variants found across the MPN patient population. INCA035784 also exhibits a low-risk profile with respect to cytokine induction."
Clinical • Myeloproliferative Neoplasm • Oncology • CALR • CD123 • CD34 • CD69 • IL2RA • IL3RA • MPL
June 06, 2025
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
(clinicaltrials.gov)
- P1 | N=120 | Not yet recruiting | Sponsor: Incyte Corporation
New P1 trial • Myeloproliferative Neoplasm • Oncology
1 to 3
Of
3
Go to page
1